Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:42 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Vortioxetine 10 mg Clear all

Conditions: Generalized Anxiety Disorder
Interventions: Placebo, Vortioxetine, Duloxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 781 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 66
States / cities: Anaheim, California • Beverly Hills, California • Fresno, California + 63 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 34
States / cities: Little Rock, Arkansas • Imperial, California • Lemon Grove, California + 29 more

Conditions: Depressive Disorder, Anxiety Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Wichita, Kansas • Cincinnatti, Ohio + 1 more

Conditions: Treatment Outcome
Interventions: Vortioxetine, Escitalopram, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 53
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 50 more

Conditions: Post-Traumatic Stress Disorder
Interventions: Placebo, Vortioxetine; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: Generalized Anxiety Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 40
States / cities: Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more

Conditions: Major Depressive Disorder, Coronary Artery Disease
Interventions: Vortioxetine; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Social Anxiety Disorder, Major Depressive Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: vortioxetine (Lu AA21004), Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 62
States / cities: Tucson, Arizona • Little Rock, Arkansas • Bellflower, California + 59 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 56
States / cities: Beverly Hills, California • Chino, California • Garden Grove, California + 53 more

Conditions: Schizophrenia, Negative Symptoms
Interventions: Vortioxetine, Placebo; Drug · Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Lauderdale Lakes, Florida • Grand Rapids, Michigan • Glen Oaks, New York

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 39
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 36 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 61
States / cities: Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more

Conditions: Depression
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 11 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Long Beach, California • Atlanta, Georgia • Plano, Texas

Conditions: Unipolar Depression, Bipolar Depression
Interventions: Vortioxetine, Cariprazine (Augmentation Phase); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Beverly Hills, California • Garden Grove, California • National City, California + 11 more

Conditions: Major Depressive Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 79
States / cities: Phoenix, Arizona • Tucson, Arizona • Cerritos, California + 68 more

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Costa Mesa, California • Culver City, California • Glendale, California + 22 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions: vortioxetine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 62 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 7 Years to 18 Years
Enrollment: 662 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Tucson, Arizona • Wichita, Kansas • Cincinnati, Ohio + 1 more

Conditions: Healthy Volunteers
Interventions: Vortioxetine, Paroxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Encino, California • Long Beach, California • Torrance, California + 12 more

Conditions: Major Depressive Disorder
Interventions: Vortioxetine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 38
States / cities: Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more

Conditions: Age-related Cognitive Decline
Interventions: Vortioxetine 10 mg, Cognitive training program; Drug · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction

Vortioxetine for Posttraumatic Stress Disorder

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease

Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Adjunctive Vortioxetine in Schizophrenia

Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Vortioxetine to Prevent Return of Symptoms in Children With Depression

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

Investigating the Effect of Vortioxetine in Adult ADHD Patients

Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Vortioxetine for Menopausal Depression

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training